Immunization with CJ9-gD significantly reduced the amount and duration of wild-type virus replication as well buy X-396 as the number of genital lesions after vaginal challenge with HSV-2 compared with that in mock-immunized guinea pigs. Only 2 of 8 immunized animals developed 2 mild and fast healing herpetiform lesions with no signs of systemic involvement. Morbidity was quite extensive in mock-vaccinated animals with an average of 20.6 lesions per animal, a high incidence of systemic involvement, and a mortality rate of 90%. High mortality rates
in mock-vaccinated animals after vaginal challenge with wild-type HSV-2 have been reported by other groups [19, 41] and limit the evaluation of recurrences. The extent of disease might be influenced by the viral strain or stock, the viral titer and by the inoculation method used. Despite the extensive disease in mock-vaccinated animals, CJ9-gD provided good protection against genital challenge with wild-type HSV-2 in immunized guinea pigs. Therefore, it is reasonable to anticipate that protection would be more effective should a lower dose of challenge
virus or a more gentle inoculation be selected. In accordance with the protection against primary disease, neither recurrent vaginal shedding of infectious virus INCB024360 order nor recurrent genital lesions were found in CJ9-gD-immunized animals. Quantitative PCR analysis shows that the amount
of latent HSV DNA in dorsal root ganglia was 50-fold lower in immunized guinea pigs compared with the 2 mock-immunized guinea pigs that survived following challenge with wild-type HSV-2 (p < 0.0001). Recall that CJ9-gD cannot establish detectable latent infection in sensory ganglia PJ34 HCl in mice following ocular or intranasal infection [27] nor in dorsal root ganglia after subcutaneous immunization [29]. The viral DNA detected in dorsal root ganglia of CJ9-gD-immunized guinea pigs after vaginal challenge should be primarily the challenge wild-type HSV-2 viral DNA. Taken together, these results are consistent with observations that a reduced latent infection is associated with a lower incidence of reactivation and recurrent disease [20, 41, 42]. Several vaccine candidates have been tested in guinea pigs against genital HSV-2 infection. The subunit vaccine gD2/AS04, which contains the HSV-2 major antigen glycoprotein D (gD2) in combination with the adjuvant aluminium hydroxide and 3-O-deacylated-monophosphoryl lipid A (MPL), was effective in prevention of primary and recurrent genital disease in immunized animals following challenge with wild-type HSV-2 [19, 20].